Search

Your search keyword '"Fréderic Bloch"' showing total 3 results
Start Over Author "Fréderic Bloch"
3 results on '"Fréderic Bloch"'

1. Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status

Author

François Helle, Julien Moyet, Baptiste Demey, Catherine François, Gilles Duverlie, Sandrine Castelain, Fréderic Bloch, and Etienne Brochot

Subjects
Vaccines, COVID-19 Vaccines, General Veterinary, General Immunology and Microbiology, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, Antibodies, Viral, Antibodies, Neutralizing, Article, Immunity, Humoral, Nursing Homes, Infectious Diseases, Spike Glycoprotein, Coronavirus, Humans, Molecular Medicine, Serological assay, Humoral vaccine response, Aged
Abstract

Background Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce. Objectives We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine. Results All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463–78852] vs. 1314 [272–1249] arbitrary units, respectively; p

Published
2022
Full Text
View/download PDF

3. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.

Author

Christine A M Payan, François Viallet, Bernhard G Landwehrmeyer, Anne-Marie Bonnet, Michel Borg, Franck Durif, Lucette Lacomblez, Frédéric Bloch, Marc Verny, Jacques Fermanian, Yves Agid, Albert C Ludolph, Peter N Leigh, Gilbert Bensimon, and NNIPPS Study Group

Subjects
Medicine, Science
Abstract

The Natural History and Neuroprotection in Parkinson Plus Syndromes (NNIPPS) study was a large phase III randomized placebo-controlled trial of riluzole in Progressive Supranuclear Palsy (PSP, n = 362) and Multiple System Atrophy (MSA, n = 398). To assess disease severity and progression, we constructed and validated a new clinical rating scale as an ancillary study.Patients were assessed at entry and 6-montly for up to 3 years. Evaluation of the scale's psychometric properties included reliability (n = 116), validity (n = 760), and responsiveness (n = 642). Among the 85 items of the initial scale, factor analysis revealed 83 items contributing to 15 clinically relevant dimensions, including Activity of daily Living/Mobility, Axial bradykinesia, Limb bradykinesia, Rigidity, Oculomotor, Cerebellar, Bulbar/Pseudo-bulbar, Mental, Orthostatic, Urinary, Limb dystonia, Axial dystonia, Pyramidal, Myoclonus and Tremor. All but the Pyramidal dimension demonstrated good internal consistency (Cronbach α ≥ 0.70). Inter-rater reliability was high for the total score (Intra-class coefficient = 0.94) and 9 dimensions (Intra-class coefficient = 0.80-0.93), and moderate (Intra-class coefficient = 0.54-0.77) for 6. Correlations of the total score with other clinical measures of severity were good (rho ≥ 0.70). The total score was significantly and linearly related to survival (p

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results